Document is current
Any future updates will be listed below
-
Authors
Michael, J.
Unger, M. S.
Poupardin, R.
Schernthaner, P.
Mrowetz, H.
Attems, J.
Aigner, L. https://orcid.org/0000-0002-1653-8046
-
Funding
Funding for this research was provided by:
FWF (P 31362-B34)
- License Information
-
More Information
Article History
Received: 3 July 2020
Accepted: 4 July 2020
First Online: 8 August 2020
Ethics approval and consent to participate
: Animal care, handling, genotyping and experiments were approved by local ethical committees (BMWFW-66.019/0011-WF/V/3b/2016 and BMWFW-66.019/0032-WF/V/3b/2016).
: Human patients data are anonymized and therefore, it is not applicable.
: LA declares that he is consultant at IntelGenx corp., Canada, which has a clinical program for the development of Montelukast in AD. JM declares that she has received a PhD fellowship from IntelGenx corp. The authors declare that they have no competing interests.
